16,000 Shares in TG Therapeutics, Inc. $TGTX Acquired by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. acquired a new position in TG Therapeutics, Inc. (NASDAQ:TGTX) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 16,000 shares of the biopharmaceutical company’s stock, valued at approximately $477,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Congress Asset Management Co. bought a new position in TG Therapeutics in the 4th quarter worth approximately $57,307,000. Nordea Investment Management AB bought a new position in TG Therapeutics in the 4th quarter worth approximately $2,356,000. Penn Capital Management Company LLC grew its holdings in TG Therapeutics by 17.6% in the 3rd quarter. Penn Capital Management Company LLC now owns 521,260 shares of the biopharmaceutical company’s stock worth $18,877,000 after buying an additional 77,895 shares in the last quarter. Public Sector Pension Investment Board grew its holdings in TG Therapeutics by 14.5% in the 3rd quarter. Public Sector Pension Investment Board now owns 529,271 shares of the biopharmaceutical company’s stock worth $19,120,000 after buying an additional 66,911 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in TG Therapeutics by 56.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 227,934 shares of the biopharmaceutical company’s stock worth $8,234,000 after buying an additional 81,907 shares in the last quarter. 58.58% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Zacks Research cut TG Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Friday, May 1st. Wall Street Zen cut TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Weiss Ratings upgraded TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, May 1st. JPMorgan Chase & Co. lowered their price target on TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating on the stock in a research report on Monday, February 2nd. Finally, HC Wainwright reiterated a “buy” rating and set a $70.00 price target on shares of TG Therapeutics in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $52.50.

TG Therapeutics Stock Down 2.3%

Shares of TGTX stock opened at $37.94 on Friday. TG Therapeutics, Inc. has a 1 year low of $25.28 and a 1 year high of $44.65. The stock has a market cap of $5.81 billion, a PE ratio of 13.27 and a beta of 1.68. The business’s fifty day moving average is $36.21 and its 200-day moving average is $32.31. The company has a debt-to-equity ratio of 1.28, a quick ratio of 5.12 and a current ratio of 5.81.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by ($0.11). The firm had revenue of $204.92 million for the quarter, compared to analyst estimates of $200.33 million. TG Therapeutics had a net margin of 65.95% and a return on equity of 88.73%. The firm’s revenue for the quarter was up 69.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.03 earnings per share. Equities analysts expect that TG Therapeutics, Inc. will post 1.31 earnings per share for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.